Cited by 22Regulation of Appetite and ObesityDiabetes Treatment and ManagementPharmacology and Obesity Treatment

Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice

Open access
McMorrow, Hayley E., Cohen, Andrew B., Lorch, Carolyn M., Hayes, Nikolas W., Fleps, Stefan W., Frydman, Joshua A., Xia, Jessica L., Samms, Ricardo J. +1 more·2025·Journal of Clinical Investigation

Abstract

The incretin receptor agonists semaglutide and tirzepatide have transformed the medical management of obesity. The neural mechanisms by which incretin analogs regulate appetite remain incompletely understood, and dissecting this process is critical for the development of next-generation antiobesity drugs that are more targeted and tolerable. Moreover, the physiologic functions of incretins in appetite regulation and gut-brain communication have remained elusive. Using in vivo fiber photometry, we discovered distinct pharmacologic and physiologic roles for the incretin hormones glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1). We showed that GIP, but not GLP-1, was required for normal nutrient-mediated inhibition of hunger-promoting AgRP neurons. By contrast, both GIP and GLP-1 analogs at pharmacologic doses were sufficient to inhibit AgRP neurons. The magnitude of neural inhibition was proportional to the effect of each incretin on food intake, and dual GIP and GLP-1 receptor agonism more potently inhibited AgRP neurons and suppressed food intake than either agonist alone. Our results have revealed a role for endogenous GIP in gut-brain appetite regulation and indicate that incretin analogs act in part via AgRP neurons to mediate their anorectic effects.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci186652

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Both GIP and GLP-1 analogs at pharmacologic doses inhibit AgRP neurons in proportion to their anorexigenic action.

    “McMorrow HE et al. using in vivo fiber photometry demonstrated that both GIP and GLP-1 analogs at pharmacologic doses inhibited AgRP neurons in proportion to their anorexigenic action.”

    From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [46]

    The Results section ('GIPR and GLP-1R analogs acutely inhibit AgRP neurons'; page unavailable) reports that pharmacologic doses of both analogs inhibited AgRP neurons in mice, measured by fiber photometry. The reported correlation with feeding suppression concerns a different measure: how much pretreatment blunted the neurons’ subsequent response to food presentation. The paper does not establish that the initial drug-induced inhibition was proportional to anorexigenic action. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • Dual GIP and GLP-1 receptor agonists more potently inhibit AgRP neurons and suppress food intake than either agonist alone.

    “Notably, dual GIP and GLP-1 receptor agonists produced more potently inhibited AgRP neurons and suppressed food intake than either agonist alone (46).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
McMorrow, H. E., Cohen, A. B., Lorch, C. M., Hayes, N. W., Fleps, S. W., Frydman, J. A., Xia, J. L., Samms, R. J., & Beutler, L. R.
Affiliations
  • Northwestern University (US)
  • Eli Lilly (United States) (US)
Corresponding author
Beutler, Lisa R.
Venue
Journal of Clinical Investigation
Published
2025-08-26
Volume
135
Issue
21
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W4413682611
Cited by
12
References
65
Citations by year
2026: 11 · 2025: 1
FWCI
5.61
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • NIH (P30-DK020595,K08-DK118188,R01-DK128477)
  • American Diabetes Association (12-22-ACE-31)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
Keywords
incretin receptor agonists, semaglutide, tirzepatide, AgRP neurons, food intake regulation, appetite, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, GLP-1 receptor agonism, gut-brain signaling, obesity, anorectic effect, fiber photometry
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Animals, Eating, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Male, Neurons, Receptors, Gastrointestinal Hormone, Mice, Glucagon-Like Peptide 1, Agouti-Related Protein, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review